Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15170539 | 1.00 | USP30 (0.49) | USP30HSD11B1RECQLGPR119JAK2 | |
| SCHEMBL2763375 | 0.92 | RECQL (0.48) | RECQLGPR119HPGDUSP2SMN1; SMN2 | |
| SCHEMBL190115 | 0.86 | USP30 (0.51) | USP30HSD11B1RECQLGPR119JAK2 | |
| SCHEMBL25966188 | 0.86 | USP30 (0.51) | USP30HSD11B1RECQLGPR119JAK2 | |
| SCHEMBL31691545 | 0.82 | DDB1 (0.44) | USP30GPR119JAK2JAK1DDB1 | |
| SCHEMBL2499416 | 0.81 | USP30 (0.57) | USP30HSD11B1RECQLGPR119JAK2 | |
| SCHEMBL12071952 | 0.81 | USP30 (0.57) | USP30HSD11B1RECQLGPR119JAK2 | |
| SCHEMBL2499421 | 0.81 | USP30 (0.57) | USP30HSD11B1RECQLGPR119JAK2 | |
| Hydrochloric Acid SCHEMBL2496036 | 0.80 | USP30 (0.56) | USP30HSD11B1RECQLGPR119JAK2 | |
| SCHEMBL31691635 | 0.79 | HPGD (0.44) | USP30HSD11B1RECQLGPR119JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10369153-B2 | Pyrrolopyrimidine compounds and uses thereof | HUTCHISON MEDIPHARMA LIMITED (CN) | 2019-08-06 | — | — | US | disclosed |
| EP-2606051-B1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LTD (CN) | 2016-10-05 | — | — | EP | disclosed |
| US-9346810-B2 | Pyrrolopyrimidine compounds and uses thereof | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-05-24 | — | — | US | disclosed |
| US-20130210831-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2013-08-15 | — | — | US | disclosed |
| EP-2606051-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | Hutchison Medipharma Limited (CN) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012022265-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10369153-B2 | Pyrrolopyrimidine compounds and uses thereof | JAK2, JAK1, JAK3 | USP30 3092/4885HSD11B1 3376/4885RECQL 1408/4885 |
| US-20130210831-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND USES THEREOF | JAK2, JAK1, JAK3 | USP30 3092/4885HSD11B1 3376/4885RECQL 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.